Company intelligence / Profile preview

Harbin Pharmaceutical Group Bioengineering Co. Ltd.

Harbin, Heilongjiang Sheng, China

Ownership: Private
Development stage: Other

Overview

Approved products include recombinant human erythropoietin for anemia (approved China 2005), recombinant human granulocyte/macrophage colony-stimulating factor for leukopenia and myelodysplastic syndromes (approved China 1999), and recombinant human interferon alfa-2b for viral hepatitis and condylomata acuminata (approved China 1996).[3]

Therapeutic areas: HematologyOncologyInfectious Diseases
Modalities: BiosimilarRecombinant proteinInterferonsColony-stimulating factors
Industry: Biotech

Beyond the preview

Go deeper on Harbin Pharmaceutical Group Bioengineering Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harbin Pharmaceutical Group Bioengineering Co. Ltd..

Explore the full profile